Literature DB >> 28801971

Pharmacokinetics and metabolism of olerciamide A from Portulaca oleracea L. in rats by UHPLC-UV and UHPLC-ESI-Q-TOF/MS.

Zheming Ying1, Cuiyu Li2, Mingzhe Gao3, Xixiang Ying2, Guanlin Yang1.   

Abstract

The aim of this study was to elucidate the pharmacokinetics of olerciamide A in rats after oral and intravenous administration of Portulaca oleracea L. extract by a simple and rapid ultra high-performance liquid chromatography method with bergapten as internal standard. The pharmacokinetic results indicated that olerciamide A was rapidly distributed with a time to peak concentration of 30 min after oral administration and presented a low oral absolute bioavailability of 4.57%. The metabolism of olerciamide A in rats was also investigated using ultra-high-performance liquid chromatography electrospray coupled with quadrupole-time of flight mass spectrometry to elucidate the reason for the low absolute bioavailability of olerciamide A and seven metabolites of oleraciamide A were found in rat plasma and urine.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Portulaca oleracea L; metabolism; olerciamide A; pharmacokinetics; ultra-high performance liquid chromatography; ultra-high performance liquid chromatography electrospray quadrupole-time of flight mass spectrometry

Mesh:

Substances:

Year:  2017        PMID: 28801971     DOI: 10.1002/bmc.4061

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  2 in total

1.  Bioactivities of 7'‑ethoxy‑trans‑feruloyltyramine from Portulaca oleracea L. and its metabolism in rats using ultra‑high‑performance liquid chromatography electrospray coupled with quadrupole time‑of‑flight mass spectrometry.

Authors:  Zheming Ying; Mingyue Jiang; Lina Wang; Xixiang Ying; Guanlin Yang
Journal:  Indian J Pharmacol       Date:  2020-06-03       Impact factor: 1.200

2.  An Integrative Pharmacology-Based Approach for Evaluating the Potential Effects of Purslane Seed in Diabetes Mellitus Treatment Using UHPLC-LTQ-Orbitrap and TCMIP V2.0.

Authors:  Jinli Hou; Xiang Zhou; Ping Wang; Chunhui Zhao; Yuewen Qin; Feng Liu; Liping Yu; Haiyu Xu
Journal:  Front Pharmacol       Date:  2021-02-02       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.